



Generalitat de Catalunya
 Departament de Salut
 Institut Català

SCIENTIFIC PROGRAM

1st WORKSHOP

CLINICAL TRIALS IN NASH PATIENTS WITH COMPENSATED CIRRHOSIS

28th of April 2023 BARCELONA Virtual and in-person









Generalitat de Catalunya Departament de Salut Institut Català de la Salut

1ST WORKSHOP CLINICAL TRIALS IN NASH PATIENTS WITH COMPENSATED CIRRHOSIS

April 28th 2023

DIRECTORS:

Dr. Joan Genescà, Clinical Director of Digestive Diseases and Chief of Liver Unit, Vall d'Hebron University Hospital; Professor of Medicine, Universitat Autònoma de Barcelona; CIBERehd, Institute of Health Carlos III.

Dr. Juan M Pericàs, Consultant at Liver Unit, Vall d'Hebron University Hospital; CIBERehd Institute of Health Carlos III.

OBJECTIVES:

- 1. Overview of the current situation and regulatory requirements in NASH clinical trials
- 2. Review of endpoints for clinical trials in NASH patients with cirrhosis
- 3. Alternative options for the design of clinical trials in NASH patients with cirrhosis

VENUE:

Conference room – Floor 1 Pabellón docente Vall d'Hebron Barcelona Hospital Campus 119-129 Vall d'Hebron Avenue 08035 Barcelona, Spain



ACCREDITATION:

Accreditation requested by the **European Accreditation Council for Continuing Medical Education** (EACCME – an Institution of the UEMS) to provide continuing medical education for physicians. A certificate of assistance will be awarded to participants attending at least **80%** of the session.

REGISTRATION:

In-person registration fee:	250,00€
Virtual registration fee:	100,00€
On-demand fee:	50,00€

Lunch and coffee breaks are included.

Registrations must be made through the following website: <u>https://aula.vallhebron.com/</u> (future courses section).

Special dietary requirements must be notified to Technical Secretary during the registration process (<u>inscripcionsaulavh@vhebron.net</u>).

TECHNICAL SECRETARY: Aula Vall d'Hebron – inscripcionsaulavh@vhebron.net – +34 693785436








Generalitat de Cataluny Departament de Salu

1ST WORKSHOP CLINICAL TRIALS IN NASH PATIENTS WITH COMPENSATED CIRRHOSIS

April 28th 2023



SPEAKERS AND MODERATORS

AGUSTIN ALBILLOS

Professor of Medicine, University of Alcalá, Madrid Head, Department of Gastroenterology and Hepatology, Ramón y Cajal, University Hospital Madrid (Spain)

ALDO TRYLESINSKI Executive Medical Director Hepatology and Speciality Medicines Advanz Pharma

ANDREEA CIUDIN

Endocrinology and Nutrition Department, Morbid Obesity Unit Coordinator, Vall d'Hebron University Hospital Associated Professor of Human Physiology, Autonomous University of Barcelona Member of the Directory Board of the Spanish Society of Obesity, SEEDO Investigator of CIBERdem, Institute of Health Carlos III (Spain)

ANNALISA BERZIGOTTI

Head of Hepatology a.i. Clinic Director Department of Visceral Surgery and Medicine Inselspital, Bern University Hospital (Switzerland)

CLAUDIA DE OLIVEIRA

Clinical Development Lead, Liver Fibrosis and Cendakimab Global Drug Development | Research & Development Bristol Myers Squibb

ELMER SCHABEL

Federal Institute for Drugs and Medical Devices, Bonn (Germany)

EMMANUEL TSOCHATZIS

Professor of Hepatology UCL Institute for Liver and Digestive Health, Royal Free Hospital (United Kingdom)

FRANK TACKE

Department Head and Professor of Medicine Charité - Universitätsmedizin Berlin Department of Hepatology and Gastroenterology Campus Virchow-Klinikum (CVK) and Campus Charité Mitte (CCM) (Germany)

IAN ROWE

Associate Professor, University of Leeds Institute for Medical Research Honorary

Consultant Hepatologist at the Leeds Liver Unit, Leeds (United Kingdom)

JAUME BOSCH

Professor of Medicine, Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital (Switzerland)

JOAN GENESCÀ

Clinical Director of Digestive Diseases and Chief of Liver Unit, Vall d'Hebron University Hospital Head of the Advanced Chronic Liver Diseases Research Group, CIBERehd Institute of Health Carlos III

Professor of Medicine, Autonomous University of Barcelona (Spain)

JOSE LUIS CALLEJA

Professor of Medicine, Universidad Autónoma Madrid Chief of Gastroenterology and Hepatology units, Puerta de Hierro University Hospital, Madrid (Spain)

JUAN GONZÁLEZ-ABRALDES

Professor of Medicine – Division of Gastroenterology, University of Alberta Director, Liver Unit AHS Hepatology Lead, Edmonton Zone (Canada)

JUAN M PERICÀS

Consultant at Liver Unit, Vall d'Hebron University Hospital, Barcelona Investigator of CIBERehd Institute of Health Carlos III (Spain)

LISA BOYETTE Senior Director of Clinical Development Gilead Sciences, Inc

MÒNICA PONS Consultant at Liver Unit, Vall d'Hebron University Hospital, Barcelona (Spain)

PETER RYDQVIST Medical Director – Europe Madrigal Pharmaceuticals

QUENTIN ANSTEE Professor of Experimental Hepatology, Newcastle University, Newcastle (United Kingdom)

RAFAEL BAÑARES

Professor of Medicine, Complutense University of Madrid Chief Digestive Medicine Department, Gregorio Marañon General University Hospital Scientific Director of Liver and Digestive Diseases area, CIBERISCIII

RAMÓN BATALLER

Chief Liver Unit, Hospital Clinic, Barcelona (Spain)

RON BASUROY

Medical Director - NASH Novo Nordisk A/S

SALVADOR AUGUSTIN

Senior Clinical Program Lead - NASH Boehringer Ingelheim International GmbH (Germany)

SVEN FRANCQUE

Chairman – Division of Gastroenterology and Hepatology, Antwerp University Hospital

Senior Full Professor of Medicine – Laboratory of Experimental Medicine and Paediatrics (Faculty of Medicine and Health Sciences), University of Antwerp (Belgium)

THOMAS REIBERGER

Division of Gastroenterology and Hepatology Department of Medicine III, Medical University of Vienna Head of Liver Cirrhosis Clinic Director of Christian Doppler Lab for Portal Hypertension and Liver Fibrosis Adjunct PI at CeMM and at LBI for Rare and Undiagnosed Diseases (LBI-RUD), Vienna (Austria)

VÍCTOR VARGAS

Senior consultant at Liver Unit, Vall d'Hebron University Hospital Professor of Medicine, Autonomous University of Barcelona (Spain)

VIRGINIA HERNÁNDEZ-GEA

Hepatic hemodynamic Unit, Liver Unit, Hospital Clinic – IDIBAPS, Barcelona (Spain) Investigator of CIBERehd, Institute of Health Carlos III Secretary of VALDIG EASL Scientific committee & Governing Board ERN Rare-Liver managing team



Aula Vall d'Hebron - Secretaría Técnica actividades formativas externas inscripcionsaulavh@vhebron.net - 693785436






Generalitat de Catalunya Departament de Salut

1ST WORKSHOP CLINICAL TRIALS IN NASH PATIENTS WITH COMPENSATED CIRRHOSIS

April 28th 2023



9:00 - 9:15h Welcome: Dr. Jose Luís Calleja and Dr. Joan Genescà

9:20 - 11:00h
SESSION I. Current landscape and regulatory issues (1h 40min) Moderators: V. Vargas and A. Trylesinski

Current situation of clinical trials in NASH (20 min) – F. Tacke
Clinical trials in NASH cirrhosis: challenges (20 min) – S. Augustin
Regulatory aspects: EMA position (20 min) – E. Schabel
Regulatory aspects: FDA position (20 min) – P. Rydqvist Discussion (20 min)

11:00 - 11:20h Coffee break (20 min)

- 11:20 13:00h SESSION II. Weight loss and bariatric surgery in NASH cirrhosis (1h 40min) Moderators: R. Bañares and R. Basuroy
 1 Effects of weight loss in cirrhotic NASH patients (20 min) - A Perzicotti
 - 1. Effects of weight loss in cirrhotic NASH patients (20 min) A. Berzigotti
 - 2. Drugs for obesity in NASH patients (20 min) A. Ciudin
 - 3. Bariatric surgery in NASH: overview of results (20 min) *S. Francque*
 - 4. How to select NASH cirrhotic patients for bariatric surgery (20 min) *T. Reiberger* Discussion (20 min)
- 13:00 14:00h Lunch (60 min)
- 14:00 15:40h
 SESSION III. Endpoints in NASH cirrhosis clinical trials (1h 40min) Moderators: A. Albillos and C. Oliveira

 Liver Biopsy (20 min) – JM. Pericàs
 Surrogate endpoints: HVPG (20 min) – V. Hernández-Gea
 Other non-invasive endpoints (20 min) – Q. Anstee
 Clinical endpoints (20 min) – E. Tsochatzis
 Discussion (20 min)
- 15:40 16:00h Coffee break (20 min)

16:00 - 17:30h SESSION IV. Alternatives in design for NASH cirrhosis clinical trials (1h 30min) Moderators: J. Bosch and L. Boyette

- 1. Prognostic models in NASH cirrhosis (20 min) M. Pons
- 2. Ordinal outcomes for NASH cirrhosis clinical trials (20 min) JG. Abraldes

3. How NASH cirrhosis clinical trials might be in the future? (20 min) – *I. Rowe* Discussion all panelists (30 min)

17:30 - 17:45h Greetings & concluding remarks: Dr. Ramón Bataller and Dr. Joan Genescà








alitat de Catalunya

1ST WORKSHOP CLINICAL TRIALS IN NASH PATIENTS WITH COMPENSATED CIRRHOSIS April 28th 2023



SPONSORED BY

SAPPHIRE SPONSORSHIP



PLATINUM SPONSORSHIP









echosens

OTHER SPONSORSHIPS







Aula Vall d'Hebron - Secretaría Técnica actividades formativas externas inscripcionsaulavh@vhebron.net - 693785436